1. Healthcare

DAY 1
THURSDAY - JANUARY 29, 2015
2:00-2:10
Welcome and introduction
F. Foss
2:10-2:15
Introduction of keynote presenter
E. Jaffe
2:15-3:00
Keynote address: Clinical Research on T-cell Lymphoma in Japan
SESSION 1: Molecular Pathogenesis
Moderators: E. Jaffe, Y. Shi
K. Tobinai
3:00-3:15
The role of IDH2 mutations in T-cell Lymphoma: Is it really restricted to AITL?
T. Mak
3:15-3:30
Understanding the molecular pathogenesis of the sezary syndrome
P. Porcu
3:30-3:45
L. Couronne
4:00-4:15
Mutations in DNMT3 in PTCL: Implications for a tailored therapeutic strategy
Discrimination of mutations arising in pre-malignant cells and those in lymphoma cells in
AITL
Molecular heterogeneity of ALK-negative ALCL
4:15-4:30
Panel Discussion
3:45-4:00
M. Sakata-Yanagimoto
A.L. Feldman
4:30-4:45
Break
SESSION 2: Global epidemiology of T-cell lymphoma
Moderators: M. Federico, HQ Huang
4:45-5:00
Histopathology: Major discussing points for the next WHO classification of PTCL
E. Jaffe
5:00-5:15
C. Chiattone
5:45-6:00
T-cell lymphomas in South America
Incidence and frequencies of T/NK-cell lymphoma subtypes in American Indian/Alaska
Native peoples
Differences in incidence and trends of lymphoma, especially PTCL and ATL, in Japan and
the United States
Panel Discussion
6:15-10:00
Welcome Dinner
5:15-5:30
5:30-5:45
A. Shustov
D. Chihara
DAY 2 FRIDAY - JANUARY 30, 2015
7:00-8:00am
Continental Breakfast
8:00-8:05
Day 2 opening remarks:
O. O'Connor
SESSION 3: Biological Therapies of T-cell lymphoma
Moderators:
S. Bates, O. O’Connor
8:05-8:20
Epigenetic therapy of T/NK-cell lymphoma
H. Kimura
8:20-8:35
PD-1 and its role in T cell lymphoma
H. Kohrt
8:35-8:50
Anti-viral approaches for the management of ATL
O. Hermine
8:50-9:05
Tax-specific T-cell responses in allo-HSCT for ATL
A. Hasegawa
9:05-9:20
Chidamide, a new HDAC inhibitor, for PTCL
Y. Shi
9:20-9:35
Panel Discussion
9:30-9:45
Break
SESSION 4: Novel Drug Combination in T-cell Lymphoma
Moderators:
F. Foss, H. Kimura
9:45-10:00
Building novel combination therapies in PTCL: Moving beyond the single agents
O. O’Connor
10:00-10:15
Combination therapies: Lessons from molecularly defined solid tumor models
S. Bates
10:15-10:30
Preclinical rational for alisertib – romidepsin combinations
M. Fanale
* * AG E N D A I S N O T F I N A L A N D S U B J E C T T O C H A NG E * *
BOLDED NAMES HAVE BEEN CONFIRMED.
P a g e | 1 of 3
10:45-11:00
What is the role of chemotherapy in the era of biological agents in the treatment of
cutaneous T cell lymphoma?
Making the case for novel combinations as the future in PTCL
11:00-11:15
Brentuximab combinations: What does the future hold?
S. Ansell
11:15-11:30
Is there a potential for bendamustine to replace CHOP in T-cell lymphoma?
B. Coiffier
11:30-11:45
Panel Discussion
12:00-1:40
Lunch Symposium: Evolving Treatment Approaches in Peripheral T-cell Lymphoma
10:30-10:45
SESSION 5: Conundrums in PTCL Management
Moderators: K. Tobinai, S. Horwitz
1:45-2:00
Should we ever consider allogeneic stem cell transplant in first remission?
2:00-2:15
 T-cell lymphoma
2:15-2:30
Should CNS prophylaxis be a matter of routine in PTCL?
2:30-2:45
Panel Discussion
M. Prince
PL Zinzani
S. Smith
F. Foss
B. Pro
SESSION 6: Clinical Topics
Moderators:
PL Zinzani, M. Prince
2:45-3:00
Newer agents in CTCL
M. Duvic
3:00-3:15
Emerging trends in the treatment of nasal NK/T cell lymphoma
W S Kim
3:15-3:30
Circulating EBV DNA in NK/T-cell lymphoma
Y.L. Kwong
3:30-3:45
Role of PET/CT in the management of T/NK-cell lymphoma
HQ Huang
3:45-4:00
Extranodal variants of ATL
K. Tsukasaki
4:00-4:15
Panel Discussion
4:15-4:30
Break
SESSION 7: Poster presentations
Moderators: F. Foss, O. O’Connor, K. Tobinai
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5)
4:30-4:40
translocation
Defining characteristics of T-memory cells and dendritic cells in the CTCL
4:40-4:50
microenvironment
FoxP3-positive T-cell lymphoma arising in non-HTLV1 carrier: Clinicopathological analysis
4:50-5:00
of 11 cases of PTCL-NOS and 2 cases of mycosis fungoides
5:00-5:10
5:10-5:20
5:20-5:30
5:30-5:40
5:40-5:50
5:50-6:00
6:00-8:00
T cell lymphomas in Jordan
Excellent non clinical safety profile of IPH4102, the first anti-KIR3DL2 mAb for the
treatment of CTCL
A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the
chemotactic abilities and P13K/AKT activation
European phase 2 study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761)
in patients with previously treated peripheral T-cell lymphoma(PTCL)
Final analysis of the Ro-CHOP phase Ib/II study: Romidepsin in association with CHOP in
untreated patients with peripheral T-cell lymphoma (PTCL)
Incidence of CNS disease in peripheral T-cell lymphomas: Retrospective analysis from a
single north American institution
Poster Walk Reception
* * AG E N D A I S N O T F I N A L A N D S U B J E C T T O C H A NG E * *
BOLDED NAMES HAVE BEEN CONFIRMED.
P. Staber
C. Querfeld
A. Satou
A. Addasi
H. Sicard
T. Waldmann
PL. Zinzani
B. Coiffier
R. Safyan
P a g e | 2 of 3
DAY 3 SATURDAY - JANUARY 31, 2015
7:00-8:00am
Breakfast Symposium: TBD
8:10-8:15am
Day 3 opening remarks:
K. Tobinai
SESSION 8: Improving treatment strategies in PTCL and CTCL
Moderators:
M. Duvic, B. Pro
8:15-8:30
T-cell Project update
M. Federico
8:30-8:45
Y. Kim
9:00-9:15
Denileukin diftitox: Changing landscape and utility in CTCL
Survival of patients with relapsed or refractory PTCL based on the database in British
Columbia
Developing a treatment algorithm for relapsed PTCL: How to incorporate new drugs
9:15-9:30
Is watch and wait still standard for indolent ATL?
K. Ishitsuka
9:30-9:45
Current issues and new trends in allogeneic SCT for ATL
T. Fukushima
9:45-10:00
Panel Discussion
10:00-10:15
Break
8:45-9:00
K. Savage
S. Horwitz
SESSION 9: The industry's perspective
Moderators: F. Foss, O. O’Connor, K. Tobinai
10:15-10:30
Exportin inhibitors
10:30-10:45
IMiDs
S. Shacham,
Karyopharm
K. Foon, Celgene
10:45-11:00
IDH1/2 inhibitors
C. Bowden, Agios
11:00-11:15
PI3 kinase inhibitors
J. Adams, Infinity
11:15-11:45
Discussion
11:45-11:50
Closing remarks
11:50
Adjourn—Box Lunch
* * AG E N D A I S N O T F I N A L A N D S U B J E C T T O C H A NG E * *
BOLDED NAMES HAVE BEEN CONFIRMED.
O. O'Connor
P a g e | 3 of 3